ClinicalTrials.gg
RecruitingNCT04847505Updated Jul 18, 2024

68Ga-DOTA-TATE PET/CT Imaging in NETs

A Phase 3 interventional study of 68Ga-DOTA-TATE in Neuroendocrine Tumors, sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. Recruiting at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2020, registered Apr 2021).
  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,000
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Neuroendocrine Tumors with a site in Canada — 11 open to participants now, 20 under way, 4 of them phase 3. Neuroendocrine Tumors · Canada.

Planned enrollment
Largest of 33
5,000 · median 160
Started
2020
with 3 others
Phase 3
7 of 42
2 open now
Primary completion
2025-12
later than 4 of 19 live
Registered
31st of 42
by date
Lead sponsor
2 of 42
Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Among the 42 studies in Neuroendocrine Tumors with a site in Canada, this one has the largest planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2020, is one of 7 in phase 3, reaches primary completion later than 4 of the 19 other live ones, and was the 31st registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

11 of the 42 studies in Neuroendocrine Tumors with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neuroendocrine Tumors with a site in Canada, or all of them as a file.
02

Study summary

This clinical trial is a pragmatic study aiming to evaluate the innocuity/safety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine cancer patients. It is a single-center study, but with recruitment across all Canada. The trial is prospective, non-randomized, open-label and with no control group. The superiority of this procedure over the former standard-of-care (Octreoscan) was already established in previous and numerous studies across the world. As such, the current trial aims to gather data to further support the implementation of 68Ga-DOTA-TATE as the new standard-of-care for neuro-endocrine tumors (NET).

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • 68Ga-DOTA-TATE
  • PET imaging
  • Pragmatic study
  • Neuroendocrine tumors (NET)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical requisition for a 68Ga-DOTA-TATE PET/CT signed by a referring doctor
  2. Patients with suspected or proven tumors expressing somatostatin receptors
  3. by patient (or parents if patient is less than 18 years of age)

Exclusion criteria

Exclusion Criteria:

  1. *Pregnancy (not an absolute exclusion). See below*.
  2. Patient refusal to participate.
  3. Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.

    • In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an in-depth discussion with the treating physicians and the patient. In this context, any clinical situation in which the patient's life would be at stake by excluding her from the study would be considered. The conditions to decide whether to include the patient would be:

      • Severe medical condition involving the life of the pregnant woman and/or the fetus;
      • Existing treatments that are ineffective or may present toxicity to the woman and/or fetus;
      • High clinical suspicion of a somatostatin receptor overexpressing tumour;
      • Negative, indeterminate or imaging tests;
      • Therapeutic gesture considered during pregnancy based on the results of the examination, which may include termination of pregnancy or premature delivery;
      • Documented discussion with the treating team and the patient;
      • Patient agrees.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    Neuroendocrine cancer patients

    All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.

    Diagnostic Test: 68Ga-DOTA-TATE

Interventions

  • Diagnostic test68Ga-DOTA-TATE

    The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.

    Also known as: Netspot

06

What researchers measure

Primary outcomes

  1. Safety profile of 68Ga-DOTA-TATE

    Following the injection, the patient will be explicitly reminded of possible symptoms and undesirable events. The patient will be advised to inform the study personnel of the occurrence of any events, at the most opportune time. The patient will be instructed to call the local nuclear medicine study coordinator for any undesirable event that may occur for 48 hours after the PET/CT scan. Safety will be assessed by compiling all reported adverse events. Adverse events reported by patients or observed by the investigator will be recorded in the patients' CRFs, the AE database, and reported to the research manager.

    Time frame: 5 years

Secondary outcomes

  1. Generate clinical information on the impact of 68Ga-DOTA-TATE for NET patient management

    Neuroendocrine tumors (NET) used to be difficult to diagnose early with conventional methods, but with the advent of new-generation Somatostatin Receptor radioligands such as 68Ga-DOTA-TATE precise and early detection is now frequent. This trial offers the opportunity to evaluate the impact of this state-of-the-art diagnostic procedure on the management of NET patients on a large, nation-wide cohort. As such, the research team will monitor the clinical gain of 68Ga-DOTA-TATE on the diagnostic and management of NETs regarding sensitivity, specificity and accuracy compared to previous diagnostic methods.

    Time frame: 5 years

  2. Instigate the routine standard-of-care use of 68Ga-DOTA-TATE for NET patients

    Clinical and scientific evidences showed that 68Ga-DOTA-TATE is vastly superior as a diagnostic tool than the current standard-of-care Octreoscan. As such, this trial aims to implement 68Ga-DOTA-TATE as the new standard-of-care for precision diagnostic of NETs. In order to do so, health policy agencies (most notably Health Canada) will be notified about the gains (or the flaws if any) of 68Ga-DOTA-TATE over the current standard-of-care (Octreoscan) for the precise diagnostic and follow-up of NETs that will be observed during the present study. The safety profile and diagnostic accuracy assessed in Outcome 1 and 2 will be used to convince the authorities of the net benefit of using this procedure rather than the "old" standard-of-care.

    Time frame: 5 years

07

Study locations

2 of 2 sites recruiting
  • Centre Intégré Universitaire de Santé et des Services Sociaux du Centre de l'Ouest de Montréal - Jewish General Hospital
    Montréal, Quebec H3T 1E2, Canada
    Recruiting
    • Gad Abikhzer, MD · Contactgad101@hotmail.com · 514-340-8222
    • Gad Abikhzer, MD · Sub investigator
  • CHUS
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2025, 71 months after the start.

Of 25 phase 3 interventional studies under Neuroendocrine Tumors, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 85. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 19, 2021
StartActual
Jan 1, 2020
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04847505
Lead sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Collaborators
Université de Sherbrooke, Jewish General Hospital
Responsible party
Dr Éric E Turcotte, MD (Head of the clinical research, CIMS, CHUS, Centre de recherche du Centre hospitalier universitaire de Sherbrooke) — Principal investigator
First posted
Apr 19, 2021
Start date
Jan 1, 2020
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 18, 2024

Study contacts

Stéphanie Dubreuil
Contact
Stephanie.Dubreuil2@usherbrooke.ca
819-346-1110 ext. 16617
Éric E Turcotte, MD
principal investigator · Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion